Cart
sales@molnova.com
GDC-0941
CAS No. 957054-30-7
GDC-0941 ( Pictilisib )
Catalog No. M16834 CAS No. 957054-30-7
A potent, selective, orally bioavailable inhibitor of class I PI3Ks with IC50 of 3/33/3/75 nM for p110α/β/γ/δ, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 34 | In Stock |
|
| 10MG | 45 | In Stock |
|
| 50MG | 58 | In Stock |
|
| 100MG | 90 | In Stock |
|
| 200MG | 162 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGDC-0941
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective, orally bioavailable inhibitor of class I PI3Ks with IC50 of 3/33/3/75 nM for p110α/β/γ/δ, respectively.
-
DescriptionA potent, selective, orally bioavailable inhibitor of class I PI3Ks with IC50 of 3/33/3/75 nM for p110α/β/γ/δ, respectively; shows similar activity for mutant p110α E545K and H1047R (IC50=3 nM), weak or little activity for C2α, Vps34, DNA-PK, and mTOR (IC50>500 nM); inhibits Akt (Ser473) phosphorylation in U87MG, PC3, and MDA-MB-361 cells with IC50s of 46, 37, and 28 nM, respectively, and respective GI50 is 0.95, 0.28, and 0.72 uM; exhibits tumor growth inhibition in U87MG human glioblastoma xenografts.Breast Cancer Phase 2 Clinical
-
SynonymsPictilisib
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptormTOR;p110α;p110β;p110γ;p110δ
-
Research AreaCancer
-
IndicationBreast Cancer
Chemical Information
-
CAS Number957054-30-7
-
Formula Weight513.64
-
Molecular FormulaC23H27N7O3S2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 29 mg/mL
-
SMILESCS(=O)(=O)N1CCN(CC2=CC3=C(S2)C(=NC(=N3)C2=C3C=NNC3=CC=C2)N2CCOCC2)CC1
-
Chemical NameThieno[3,2-d]pyrimidine, 2-(1H-indazol-4-yl)-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-(4-morpholinyl)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Folkes AJ, et al. J Med Chem. 2008 Sep 25;51(18):5522-32.
2. Junttila TT, et al. Cancer Cell. 2009 May 5;15(5):429-40.
3. Raynaud FI, et al. Mol Cancer Ther. 2009 Jul;8(7):1725-38.
2. Junttila TT, et al. Cancer Cell. 2009 May 5;15(5):429-40.
3. Raynaud FI, et al. Mol Cancer Ther. 2009 Jul;8(7):1725-38.
molnova catalog
related products
-
AMG 511
A potent, efficacious, and orally available pan class I PI3K inhibitor.
-
LX-2343
LX-2343 is an non-ATP competitive PI3K inhibitor that negatively regulates AKT/mTOR signaling.
-
TG100-115
A potent, selective PI3Kγ/δ with IC50 of 83/235 nM, respectively; shows no significant inhibitory activity against pI3Kα and β, and a broad panel of kinases (IC50>1 uM).
